Chemomab Therapeutics Holds Annual Shareholder Meeting

TL;DR

Chemomab held its shareholder meeting on June 10, 2024.

AI Summary

Chemomab Therapeutics Ltd. (the "Company") held its annual general shareholders meeting on June 10, 2024. The company, formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd., is a foreign private issuer based in Tel Aviv, Israel, and files under Form 20-F.

Why It Matters

This filing confirms the completion of the company's annual general meeting, a routine but important event for corporate governance and shareholder engagement.

Risk Assessment

Risk Level: low — This filing is a routine report of a shareholder meeting and does not contain new financial or operational information that would typically increase risk.

Key Players & Entities

• Chemomab Therapeutics Ltd. (company) — Registrant
• Anchiano Therapeutics Ltd. (company) — Former Company Name
• BioCancell Ltd. (company) — Former Company Name
• June 10, 2024 (date) — Date of Annual General Shareholders Meeting

FAQ

Filing Documents

• zk2431582.htm (6-K) — 10KB
• 0001178913-24-001986.txt ( ) — 12KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant's name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE Chemomab Therapeutics Ltd. (the "Company") hereby furnishes the results of its annual general shareholders meeting (the "Meeting"), which was held on June 10, 2024, at 4:30 p.m. (Israel time), at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel. At the Meeting, the Company's shareholders voted upon and approved, by the requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company's articles of association (the "Articles"), the following proposals: (i) the re-election of each of Dr. Alan Moses and Dr. Adi Mor as Class III directors, (ii) an increase of the Company's authorized share capital and the amendment of the Company's Articles accordingly, (iii) the re-appointment of Somekh Chaikin, a member firm of KPMG international, as the Company's independent registered public accounting firm for the fiscal year ended December 31, 2024; all in accordance with the Company's proxy statement related to the Meeting, which was attached as Exhibit 99.1 to the Company's Report of Foreign Private Issuer on Form 6-K furnished to the Securities and Exchange Commission on May 3, 2024. This Form 6-K is incorporated by reference into the Company's Registration Statements on Form F-3 (File No. 333-275002) and Form S-8 (File No. 333-259489 and No. 333-266868). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CHEMOMAB THERAPEUTICS LTD. Date: June 12, 2024 By: /s/ Sigal Fattal Sigal Fattal Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR